speb/financial-data huggingface dataset:
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 36636300000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Assets: 1463900000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 1125600000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 124912099.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 1461600000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 607700000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 36518800000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Intangible Assets: 133200000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 152300000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Liabilities: 21700000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 14380200000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Receivables: 202000000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 6935900000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Payables: 4760800000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 124912099.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 36769500000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 36636300000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 47905000000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 36769500000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 327900000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 36769500000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 11135500000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 19957200000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 2045400000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 552000000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 18857700000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — +Operating Expense: 3011400000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — +Total Revenue: 11461300000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Basic Average Shares: 125204301.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Basic EPS: 18.60
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Cost Of Revenue: 2578100000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Depreciation And Amortization In Income Statement: 359700000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Depreciation Income Statement: 359700000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 125271651.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Diluted EPS: 18.59
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: 2328800000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — EBIT: 3153000000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — EBITDA: 3512700000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Gross Profit: 8883200000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Interest Expense: 79100000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Interest Expense Non Operating: 79100000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Net Income: 2328800000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: 2328800000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: 2328800000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 2328800000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 2328800000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: 2328800000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Net Interest Income: -79100000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: -79100000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Normalized EBITDA: 3512700000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Normalized Income: 2328800000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Operating Income: 5871800000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Operating Revenue: 11461300000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: -2894700000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 3023200000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Pretax Income: 3073900000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Reconciled Cost Of Revenue: 2578100000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 359700000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Tax Provision: 745100000.00
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.24
AJANTPHARM.NS income_statement (quarterly, 2024-12-31) — Total Expenses: 5589500000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — +Operating Expense: 23319000000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 3195600000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — +Total Revenue: 45875100000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 11704100000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 4542000000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 4542000000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 11827400000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 11827400000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -10024700000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -10024700000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 43100000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 43100000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -58900000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -58900000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Amortization: 82200000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 82200000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Assets Held For Sale Current: 133300000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Assets Held For Sale Current: 133300000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 32000000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 32000000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Average Dilution Earnings: 0.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 125126706.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 125144444.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Basic EPS: 73.56
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 18.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 1294900000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 8722800000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 8722800000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -3179200000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Capital Expenditure Reported: -3179200000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 448300000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 448300000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 250700000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 250700000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 1751200000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 1751200000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 6138300000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 6138300000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -3493700000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 1751200000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 1751200000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Change In Inventory: -745100000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Change In Payable: 1071900000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Change In Receivables: 1057700000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: 1789300000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Changes In Cash: 473000000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Common Stock: 250700000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 250700000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 37902900000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 37902900000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Common Stock Issuance: 100000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Common Stock Payments: -3513400000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 1849400000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 1849400000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 11271500000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 2834200000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Current Assets: 28430300000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 28430300000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 101100000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 101100000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Current Debt: 25900000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 25900000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 127000000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 127000000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Current Deferred Taxes Liabilities: 405300000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Deferred Taxes Liabilities: 405300000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 9961000000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 9961000000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 2631800000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 2631800000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Depreciation: 1358900000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 1441100000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 1441100000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 397800000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 1358900000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 397800000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 125176214.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 125144444.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Diluted EPS: 73.53
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 18.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 9203900000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 2252600000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 11000000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 11000000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — EBIT: 12098900000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — EBIT: 2754800000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — EBITDA: 13540000000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — EBITDA: 3152600000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — End Cash Position: 1767900000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 252400000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 252400000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -7334100000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 5274200000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 5274200000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 8393100000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: -25200000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: 6000000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 1571200000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 465200000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 465200000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 11886300000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 11886300000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 29029200000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 29029200000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Gross Profit: 34603600000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 8869900000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Hedging Assets Current: 0.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Hedging Assets Current: 0.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Interest Expense: 207300000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 60700000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 207300000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 60700000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Interest Income: 471600000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 471600000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -173100000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Inventory: 9038500000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 9038500000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 37928800000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 37928800000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -3765200000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 284400000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 284400000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Investmentsin Joint Venturesat Cost: 0.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Investmentsin Joint Venturesat Cost: 0.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Issuance Of Capital Stock: 100000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 2093000000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 2093000000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 347200000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 347200000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 347200000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 347200000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Equity Investment: 0.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 0.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 802700000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 802700000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 16364000000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 16364000000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Net Business Purchase And Sale: -62500000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: -3513300000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: -103100000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Net Income: 9203900000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income: 2252600000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 9203900000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 2252600000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 9203900000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 2252600000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 9203900000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 2252600000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 9203900000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 2252600000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 11891600000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 9203900000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 2252600000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Net Interest Income: 264300000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -60700000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: -975700000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: 11000000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: 11000000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: 264300000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -60700000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Net Other Financing Charges: -16100000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Net Other Investing Changes: 440800000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Net PPE: 19004500000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 19004500000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: 11400000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 37437700000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 37437700000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Revenue: 20000000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 20000000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 1864300000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 1864300000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 1105200000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 1105200000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 802700000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 802700000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 55400000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 55400000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 13520800000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 3152600000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Normalized Income: 9189039200.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 2252600000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 11572300000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Operating Income: 11284600000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Operating Income: 5674300000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Operating Revenue: 45875100000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 11704100000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 124912099.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 124912099.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 1233000000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 1233000000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 911200000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 911200000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 51800000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 51800000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 465200000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 465200000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Inventories: 497700000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Inventories: 497700000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: -236800000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: -100000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: -100000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Non Current Liabilities: 20000000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 20000000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 41400000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: -2990100000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 6897200000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: -2422500000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Payable: 1249500000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 1249500000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Properties: 17155000000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 17155000000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 227900000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 227900000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 4387100000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 4387100000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Other Special Charges: 6000000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Payables: 5802500000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Payables: 5802500000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 233500000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 233500000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 783900000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 783900000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Pretax Income: 11891600000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 2694100000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Purchase Of Business: -62500000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: -27612100000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 2811100000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 2811100000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 11271500000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 2834200000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 1441100000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 397800000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 93300000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 93300000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Repurchase Of Capital Stock: -3513400000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 11200000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 11200000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 36718800000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 36718800000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 26636400000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 11400000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 3020000000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 4591200000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Share Issued: 124912099.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 124912099.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Special Income Charges: -6000000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Stock Based Compensation: 38800000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 37902900000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 37902900000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 37437700000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 37437700000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 4339200.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Tax Provision: 2687700000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 441500000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.23
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.16
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Taxes Receivable: 269800000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 269800000.00
AJANTPHARM.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -3229700000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Total Assets: 50149500000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 50149500000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 37902900000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 37902900000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Total Debt: 474200000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 474200000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 37902900000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 37902900000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Total Expenses: 34590500000.00
AJANTPHARM.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 6029800000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 12246600000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 12246600000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 21719200000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 21719200000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 2285600000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 2285600000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 405300000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 405300000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 19200000.00
AJANTPHARM.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 19200000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Tradeand Other Payables Non Current: 10500000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Tradeand Other Payables Non Current: 10500000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Work In Process: 455500000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 455500000.00
AJANTPHARM.NS balance_sheet (annual, 2025-03-31) — Working Capital: 18469300000.00
AJANTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 18469300000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 3441900000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 13026500000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 124921722.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 20.44
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 2758800000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 412900000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 412900000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 124982868.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 20.43
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 2553400000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — EBIT: 3363900000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — EBITDA: 3776800000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 10267700000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 52600000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 52600000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income: 2553400000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 2553400000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 2553400000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 2553400000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 2553400000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 2553400000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -52600000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -52600000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 3776800000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 2553400000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Operating Income: 6825800000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 13026500000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: -3304200000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 3311300000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 2758800000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 412900000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 757900000.00
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.23
AJANTPHARM.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 6200700000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 3740300000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 13748400000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 124952077.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 21.91
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 2862600000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 435100000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 435100000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 124952077.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 21.91
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 2737700000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — EBIT: 3637000000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — EBITDA: 4072100000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 10885800000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 51000000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 51000000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income: 2737700000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 2737700000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 2737700000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 2737700000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 2737700000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 2737700000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -51000000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -51000000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 4072100000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 2737700000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Operating Income: 7145500000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 13748400000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: -3594000000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 3758200000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 3586000000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 2862600000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 435100000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 848300000.00
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.24
AJANTPHARM.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 6602900000.00
AJANTPHARM.NS income_statement (annual, 2026-03-31) — +Operating Expense: 28329600000.00
AJANTPHARM.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 3860900000.00
AJANTPHARM.NS income_statement (annual, 2026-03-31) — +Total Revenue: 54072600000.00
AJANTPHARM.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 14216400000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 5443000000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 5443000000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 18538800000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 18538800000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Accumulated Depreciation: -11293300000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -11293300000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Additional Paid In Capital: 78100000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 78100000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -58900000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -58900000.00
AJANTPHARM.NS income_statement (annual, 2026-03-31) — Amortization: 129100000.00
AJANTPHARM.NS cash_flow (annual, 2026-03-31) — Amortization Cash Flow: 129100000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Assets Held For Sale Current: 0.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Assets Held For Sale Current: 0.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 13300000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 13300000.00
AJANTPHARM.NS income_statement (annual, 2026-03-31) — Average Dilution Earnings: 0.00
AJANTPHARM.NS income_statement (annual, 2026-03-31) — Basic Average Shares: 124928019.00
AJANTPHARM.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 124918033.00
AJANTPHARM.NS income_statement (annual, 2026-03-31) — Basic EPS: 84.53
AJANTPHARM.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 21.35
AJANTPHARM.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 1751200000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Buildings And Improvements: 9287500000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Buildings And Improvements: 9287500000.00
AJANTPHARM.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -3651600000.00
AJANTPHARM.NS cash_flow (annual, 2026-03-31) — Capital Expenditure Reported: -3651600000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 481800000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 481800000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 250700000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 250700000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 1032600000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 1032600000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 6631100000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 6631100000.00
AJANTPHARM.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -3497200000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Cash Financial: 1032600000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Cash Financial: 1032600000.00
AJANTPHARM.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -309500000.00
AJANTPHARM.NS cash_flow (annual, 2026-03-31) — Change In Payable: 1500700000.00
AJANTPHARM.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -7496600000.00
AJANTPHARM.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -6529300000.00
AJANTPHARM.NS cash_flow (annual, 2026-03-31) — Changes In Cash: -676500000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Common Stock: 250700000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 250700000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 45270900000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 45270900000.00
AJANTPHARM.NS cash_flow (annual, 2026-03-31) — Common Stock Issuance: 0.00
AJANTPHARM.NS cash_flow (annual, 2026-03-31) — Common Stock Payments: 0.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 2951400000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 2951400000.00
AJANTPHARM.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 12477000000.00
AJANTPHARM.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 3048100000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Current Assets: 37354300000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 37354300000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 87600000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 87600000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Current Debt: 2119900000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 2119900000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 2207500000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 2207500000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Current Deferred Taxes Liabilities: 54900000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Deferred Taxes Liabilities: 54900000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 14157500000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 14157500000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 2763000000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 2763000000.00
AJANTPHARM.NS cash_flow (annual, 2026-03-31) — Depreciation: 1602300000.00
AJANTPHARM.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 1731400000.00
AJANTPHARM.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 1731400000.00
AJANTPHARM.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 453700000.00
AJANTPHARM.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 1602300000.00
AJANTPHARM.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 453700000.00
AJANTPHARM.NS income_statement (annual, 2026-03-31) — Diluted Average Shares: 124952236.00
AJANTPHARM.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 124976570.00
AJANTPHARM.NS income_statement (annual, 2026-03-31) — Diluted EPS: 84.51
AJANTPHARM.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 21.34
AJANTPHARM.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 10560000000.00
AJANTPHARM.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 2667000000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Dividends Payable: 12000000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Dividends Payable: 12000000.00
AJANTPHARM.NS income_statement (annual, 2026-03-31) — EBIT: 13937600000.00
AJANTPHARM.NS income_statement (quarterly, 2026-03-31) — EBIT: 3494700000.00
AJANTPHARM.NS income_statement (annual, 2026-03-31) — EBITDA: 15669000000.00
AJANTPHARM.NS income_statement (quarterly, 2026-03-31) — EBITDA: 3948400000.00
AJANTPHARM.NS cash_flow (annual, 2026-03-31) — End Cash Position: 1074700000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 285000000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 285000000.00
AJANTPHARM.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -1679200000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Finished Goods: 4950400000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Finished Goods: 4950400000.00
AJANTPHARM.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: 1640300000.00
AJANTPHARM.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: 786700000.00
AJANTPHARM.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of PPE: 18700000.00
AJANTPHARM.NS income_statement (annual, 2026-03-31) — General And Administrative Expense: 1625700000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 415800000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 415800000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Gross Accounts Receivable: 18597700000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 18597700000.00
AJANTPHARM.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 32498400000.00
AJANTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 32498400000.00
AJANTPHARM.NS income_statement (annual, 2026-03-31) — Gross Profit: 41595600000.00
AJANTPHARM.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 11168300000.00